Haemonetics is exploding higher today, extending gains that began on October 8 when the stock initially jumped over 13% to $115.20. The rally is driven by the announcement that CSL Plasma plans to transition its U.S. collection centers to Haemonetics' devices, significantly expanding the scope of their existing supply agreement. While the company also saw the publication of real-world analysis regarding treatment satisfaction on October 5, the CSL partnership serves as the primary catalyst for the sustained upward momentum. The broader medical device sector remains largely muted, indicating that this move is driven by company-specific developments rather than industry-wide trends.